Syngene International Ltd Stock Price Today (NSE: SYNGENE)
Syngene International Ltd
Fundamental Score
Syngene International Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Syngene International Ltd share price today is ₹432.90, up +0.00% on NSE/BSE as of 17 February 2026. Syngene International Ltd (SYNGENE) is a Large-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹25.99K (Cr). The 52-week high for SYNGENE share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 55.50x, SYNGENE is currently trading above its industry average P/E of 45.95x. The company has a Return on Equity (ROE) of 10.53% and a debt-to-equity ratio of 0.12.
Syngene International Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Syngene International Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Syngene International Share Price: A Financial Analysis
The Healthcare Research, Analytics & Technology sector is experiencing a shift towards specialized service providers, driven by the increasing complexity of drug discovery and development. This analysis examines the current financial standing of Syngene International share price, currently trading at ₹447.649994, and its competitive positioning within this dynamic landscape. Our assessment considers key financial ratios and comparisons with its peers.
Syngene International Ltd boasts a Price-to-Earnings (PE) ratio of 55.5. This is a relatively high multiple, suggesting investor expectations of future growth. When considering peer comparisons, the management quality and strategic execution of Syngene are crucial. Unlike
NOVELIX PHARMACEUTICALS LIMITE, which may be facing challenges in capital allocation, Syngene's management appears to be focused on sustainable growth and efficient resource utilization. However, a deeper dive into both companies' management track record and strategic decisions is recommended to confirm this observation.The company's Return on Capital Employed (ROCE) stands at 13.52%. This is a key indicator of profitability and efficiency. ROCE, in essence, demonstrates how well a company generates profit from its capital. A consistent and relatively high ROCE, such as Syngene's, can contribute to building a strong economic moat by signaling its ability to efficiently allocate capital and earn superior returns compared to its competitors. However, maintaining and improving upon this ROCE will be critical for solidifying its long-term competitive advantage, especially when considered against peers such as Suven Life Sciences Ltd and Fabtech Tech.
This financial analysis is part of a comprehensive 80-parameter fundamental audit, meticulously verified by Sweta Mishra. The observations presented here are based on publicly available data and are intended for informational purposes only. No investment recommendations are made.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Syngene International Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SYNGENE across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (29.64%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (12.60% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.12)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12.45x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1615.90 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (52.68%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 40.93%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 55.50x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-36.76%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Syngene International Ltd Financial Statements
Comprehensive financial data for Syngene International Ltd including income statement, balance sheet and cash flow
About SYNGENE (Syngene International Ltd)
Syngene International Ltd (SYNGENE) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Healthcare Research, Analytics & Technology sector with a current market capitalisation of ₹25.99K (Cr). Syngene International Ltd has delivered a Return on Equity (ROE) of 10.53% and a ROCE of 13.52%. The debt-to-equity ratio stands at 0.12, reflecting the company's capital structure. Investors tracking SYNGENE share price can monitor key metrics including P/E ratio, promoter holding of 52.68%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
SYNGENE Share Price: Frequently Asked Questions
What is the current share price of Syngene International Ltd (SYNGENE)?
As of 17 Feb 2026, 10:24 am IST, Syngene International Ltd share price is ₹432.90. The SYNGENE stock has a market capitalisation of ₹25.99K (Cr) on NSE/BSE.
Is SYNGENE share price Overvalued or Undervalued?
SYNGENE share price is currently trading at a P/E ratio of 55.50x, compared to the industry average of 45.95x. Based on this relative valuation, the Syngene International Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SYNGENE share price?
The 52-week high of SYNGENE share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Syngene International Ltd share price?
Key factors influencing SYNGENE share price include quarterly earnings growth (Sales Growth: 2.20%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Syngene International Ltd a good stock for long-term investment?
Syngene International Ltd shows a 5-year Profit Growth of 5.71% and an ROE of 10.53%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.12 before investing in SYNGENE shares.
How does Syngene International Ltd compare with its industry peers?
Syngene International Ltd competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare SYNGENE share price P/E of 55.50x and ROE of 10.53% against the industry averages to determine competitive standing.
What is the P/E ratio of SYNGENE and what does it mean?
SYNGENE share price has a P/E ratio of 55.50x compared to the industry average of 45.95x. Investors pay ₹56 for every ₹1 of annual earnings.
How is SYNGENE performing according to Bull Run's analysis?
SYNGENE has a Bull Run fundamental score of 41.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SYNGENE belong to?
SYNGENE operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Syngene International Ltd share price.
What is Return on Equity (ROE) and why is it important for SYNGENE?
SYNGENE has an ROE of 10.53%, which shows decent profitability but room for improvement. ROE measures how efficiently Syngene International Ltd generates profits from shareholders capital.
How is SYNGENE debt-to-equity ratio and what does it indicate?
SYNGENE has a debt-to-equity ratio of 0.12, which indicates conservative financing with low financial risk.
What is SYNGENE dividend yield and is it a good dividend stock?
SYNGENE offers a dividend yield of 0.19%, meaning you receive ₹0.19 annual dividend for every ₹100 invested in Syngene International Ltd shares.
How has SYNGENE share price grown over the past 5 years?
SYNGENE has achieved 5-year growth rates of: Sales Growth 12.60%, Profit Growth 5.71%, and EPS Growth 5.58%.
What is the promoter holding in SYNGENE and why does it matter?
Promoters hold 52.68% of SYNGENE shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Syngene International Ltd.
What is SYNGENE market capitalisation category?
SYNGENE has a market capitalisation of ₹25986 crores, placing it in the Large-cap category.
How volatile is SYNGENE stock?
SYNGENE has a beta of N/A. A beta > 1 suggests the Syngene International Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SYNGENE operating profit margin trend?
SYNGENE has a 5-year average Operating Profit Margin (OPM) of 29.64%, indicating the company's operational efficiency.
How is SYNGENE quarterly performance?
Recent quarterly performance shows Syngene International Ltd YoY Sales Growth of 2.20% and YoY Profit Growth of -36.76%.
What is the institutional holding pattern in SYNGENE?
SYNGENE has FII holding of 16.31% and DII holding of 24.62%. Significant institutional holding often suggests professional confidence in the Syngene International Ltd stock.